Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
In this study we described our real-world experience of ICIs for the treatment of patients with advanced non oncogene NSCLC. A decreased OS in our study population was reported as compared to that of patients included in the clinical trials. Noteworthy, correlations between clinical-pathological characteristics and survival outcomes emerged. Nevertheless, the potential integration of clinical-pathological characteristics as predictive biomarkers in more accurate therapeutic algorithms as well as the underlying biological mechanisms should be further validated in ad hoc studies.
Authors
- Francesco Sabbatino (ORCID: https://orcid.org/0000-0001-6431-8278)
- Giovanna Polcaro (ORCID: https://orcid.org/0000-0002-2329-3200)
- Danilo Malandrino (ORCID: https://orcid.org/0000-0002-1053-5178)
- Valeria Conti (ORCID: https://orcid.org/0000-0001-6964-2739)
- Luigi Liguori (ORCID: https://orcid.org/0000-0002-0232-1452)
- Marco Cascella (ORCID: https://orcid.org/0000-0002-5236-3132)
- Roberto Bianco (ORCID: https://orcid.org/0000-0003-3311-260X)
- Francesco Perri (ORCID: https://orcid.org/0000-0001-8158-7509)
- Alberto Servetto (ORCID: https://orcid.org/0000-0003-3624-224X)
- Stefano Pepe (ORCID: https://orcid.org/0000-0003-0057-8411)
- Alessandro Ottaiano (ORCID: https://orcid.org/0000-0002-2901-3855)
- Giovanni De Giorgio
- Valentina Pagliara (ORCID: https://orcid.org/0000-0001-9320-6080)
Institutions
- University of Salerno (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fimmu.2024.1419544
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98